Slides
Page 1
©2026 Kyverna Therapeutics, Inc. Positive Longer-Term Durability and Safety Data of Miv-cel in SPS and gMGSeptember 24, 2026
Page 2
2 ©2026 Kyverna Therapeutics, Inc. This presentation contains forward-looking statements that are based on management’s beliefs and assumptions and information currently available to management of Kyverna Therapeutics, Inc. (“Kyverna”, “we”, “our,” or the “Company”). All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward looking statements include, but are not limited to, statements concerning: the Company’s future results of operationsand financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, named-patient access data, ongoing clinical trials, research and development costs, plans for manufacturing, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed or may subsequently file with the U.S. Securities and Exchange Commission. Actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. When evaluating Kyverna’s business and prospects, careful consideration should be given to these risks and uncertainties.These statements speak only as of the date of this presentation, and Kyverna undertakes no obligation to update or revise these statements.This presentation also contains estimates made by independent parties relating to industry market size and other data. These estimates involve a number of assumptions and limitations and you are cautioned not to give undue weight on such estimates. We have not independently verified the accuracyorcompleteness of such information, and we do not take any responsibility for the accuracy or completeness of such information.This presentation contains references to trademarks and marks belonging to other entities. Solely for convenience, trademarksand trade names referred to in this presentation may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. The Company does not intend its use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of the Company by any other companies.This presentation includes results from named-patient basis access. Similar to expanded access or compassionate use in the United States, “IH” or “IndividuellerHeilversuch,” also known as “named-patient basis access,” is a regulatory scheme in Germany that allows for the supply of a treatment that has not received marketing authorization for an individual patient in response to a request by the treating physician on behalf of the named patient. This option can be pursued for theexpected benefit of a patient who has exhausted all available treatment options, under the discretion of the treating physician, with the patient’s consent. The use of miv-cel in the IH settings is not a substitute for, or intended to replace, our clinical trials. The goal is not to assess the effectiveness of a therapy, but rather to provide an individual patient with a possible efficacious approach when all other treatment options have failed, as determined by the patient’s physician. While we do not expect to be able to use the results from these activities as the basis for approval in our applications for marketing approval to the U.S. Food and Drug Administration (FDA) or other foreign regulatory agencies, we believe such activities may provide additional clinical insights beyond highly focused clinical trials in specific geographies. Disclaimer and Forward-Looking Statements
Page 3
3 ©2026 Kyverna Therapeutics, Inc. Today’s Agenda Warner BiddleChief Executive Officer Naji Gehchan, M.D., MSc, MBAChief Medical & Development Officer Miv-cel – Setting a New Benchmark for Autoimmune CAR T Stiff Person Syndrome (SPS) – 1-Year Topline Data Generalized Myasthenia Gravis (gMG) – Phase 2 Longer-term Topline Follow-up Data Transforming the Treatment Paradigm in Neurologic Autoimmune Diseases Q&A Speakers
Page 4
4 ©2026 Kyverna Therapeutics, Inc. Single Dose Miv-cel Continues to Establish a New Clinical Response Benchmarkfor Autoimmune CAR T Durable results for at least 1 year in both SPS and gMG with nearly all patients remaining off chronic immunotherapies Potential for broad immune reset through deep B-cell depletion achieved with a single dose underscores miv-cel’s unique construct and differentiated profile Data further strengthens SPS BLA; submission expected Q4 2026, paving way for the first potential CAR T launch in autoimmune in 2027, unlocking a multi-billion-dollar SPS marketData further reinforces miv-cel’s differentiation in gMG; Phase 3 trial further de-risked with enrollment expected to be completed mid-2027 Consistent, well-tolerated safety profile maintained in 1-year follow-up with no high-grade CRS or ICANS and no cases of IEC-HS CRS, cytokine release syndrome; IEC-HS, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.
Page 5
5 ©2026 Kyverna Therapeutics, Inc. Miv-cel's Differentiated CAR Construct Reinforces PotentialFirst-in-Class and Best-in-Class Profile in Autoimmune Anti-CD19 scFv CD8α TM CD28 CostimCD3ζ CD8α Hinge Mivocabtagene Autoleucel (miv-cel)1,2•Deep depletion of peripheral and tissue-resident B cells to support broad immune reset and durable remission 3-4 •First SPSand gMG patients treated with a single dose of miv-cel achieved durable efficacy beyond 24 months without the need for chronic immunotherapies5 •>100 patients dosed with miv-cel across multiple indications6 •No high-grade CRS or ICANS3 and no IEC-HS reported6 CRS, cytokine release syndrome; CNS, central nervous system; Costim, co-stimulation; IEC-HS, Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; scFv, single-chain fragment variable; TM, transmembrane. 1. Brudno JN, et al. Nat Med. 2020;26:270-280. 2. Alabanza L, et al. Mol Ther. 2017;25:2452-2465. 3. Minopoulou I, et al. Ann Rheum Dis.2025;84(3):e4-e7. 4. Albach FN, et al. Rheumatology. 2025;64(6):4075-4077. 5. Named patient access data, Kyverna Therapeutics. 6. Data on file, Kyverna Therapeutics. Only Fully Human Autologous CD19 CAR T With CD28 Costim
Page 6
6 ©2026 Kyverna Therapeutics, Inc. Miv-cel is produced using a well-established, and validated manufacturing process similar to those used in commercially available CD19 autologous CAR T-cell therapiesDual-source U.S. manufacturing strategy >98% manufacturing success rate driven by robust process, quality systems, and technical expertise Commercial agreement with Elevate supports SPS and future commercial launches and clinical demand Established, Validated, and Scalable Manufacturing Process
Page 7
SPS – 12- Month Topline Data from KYSA-8 Registrational Trial Naji Gehchan, M.D., MSc, MBA – Chief Medical and Development Officer ©2026 Kyverna Therapeutics, Inc.
Page 8
8 ©2026 Kyverna Therapeutics, Inc. KYSA-8 Registrational Trial in SPS – Study Design N = 26•Age 18 to 75 years•Diagnosis of SPS•Inadequate response to immunomodulatory therapy•Stiffness index ≥2 Primary endpoints:•Change from baseline in T25FW at 16 weeks•Safety Secondary endpoints:change from baseline at 16 weeks•Modified Rankin Scale (mRS)•Distribution of Stiffness Index (DSI)•Hauser Ambulation Index (HAI)•Heightened Sensitivity Scale (HSS) Low-dose Cy/Flu preconditioning +Single infusion of 1×108 CAR T cells One-year Follow Up KYSA-8: Open-label, single-arm, multicenter study Cy/Flu, cyclophosphamide and fludarabine; ODD, Orphan Drug Designation; RMAT, Regenerative Medicine Advanced Therapy; T25FW, Timed 25-Foot Walk. Miv-cel SPS immunotherapies are discontinued Miv-cel Granted ODD and RMAT Designations by FDA for SPS
Page 9
9 © 2026 Kyverna Therapeutics, Inc. Continued Reversal of Disability with Nearly All Patients Remaining Off Chronic Immunotherapies Sustained Through 1 YearSignificant T25FW Improvement and Reduced Walking Aid Use None Unilateral Bilateral •95% of patients who achieved a clinically meaningful improvement (≥20%reduction from baseline)1 at primary analysis sustained their benefit at 1 year•At 1 year, over one-third of patients completed T25FW in <5 seconds, comparable to a typical time for healthy adults2•Of the 12 patients requiring a walking aid for T25FW at baseline, 67% continue not to require assistance at 1 year•92% (24/26) of patients continue to remain free of immunomodulatory or immunosuppressant therapiesfor SPS*at 1 year 0.0003 <0.000116-week primary endpointmeasurement; 46% median reduction in T25FW *Includes IVIg/SCIg, PLEX, rituximab and/or prednisone (≥20 mg/day) for SPS symptoms.N=26. Database lock: July 2026. Percentages may not total 100% due to rounding. BL, baseline; T25FW, timed 25-foot walk.1. Hobart J, et al. Neurology. 2013;80(16):1509-17. 2. Motl RW, et al. Mult Scler. 2017;23(5):704-710. 52-week follow-up; 49% median reduction in T25FW
Page 10
10 ©2026 Kyverna Therapeutics, Inc. Statistically Significant Improvements Continued in All Primary and Secondary Endpoints Through 1 Year Primary EndpointP ValueP ValueTimed 25-Foot Walk0.0003<0.0001 Secondary EndpointsP ValueP ValueModified Rankin Scale<0.00010.0003Distribution of Stiffness Index<0.0001<0.0001Hauser Ambulation Index<0.0001<0.0001Heightened Sensitivity Scale<0.0001<0.0001 16-wk timepoint1-Yr follow-up
Page 11
11 ©2026 Kyverna Therapeutics, Inc. Consistent Safety Profile Maintained in 1-Year Follow-Up With No High-Grade CRS or ICANS and No IEC-HS •No high-grade CRS or ICANS observed•No IEC-HS observed•All Grade 3/4 neutropenia (5/26), an expected AE with lymphodepletion and CAR T-cell therapies, were manageable •All treatment-related serious AEs (3/26) have fully resolved CRS, ICANS, IEC-HS assessed using ASTCT criteria; other AEs graded using CTCAE criteria. AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; IEC-HS, Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome. Treatment-Related Adverse Events, n (%)N = 26Any grade ≥3 CRS0 (0)Any grade ≥3 ICANS 0 (0)Any grade IEC-HS 0 (0)CRS (any Grade)24 (92)Grade 110 (38)Grade 214 (54)ICANS (any Grade)3 (12)Grade 13 (12)Grade 3/4 neutropenia5 (19)Any treatment-related serious AE3 (12)
Page 12
12 KYSA-8 Patient Perspectives: Before and After Treatment with Miv-cel Case Studies View Video View Video
Page 13
gMG – Longer-Term Data from Phase 2 KYSA-6 Trial Naji Gehchan, M.D., MSc, MBA – Chief Medical and Development Officer ©2026 Kyverna Therapeutics, Inc.
Page 14
14 ©2026 Kyverna Therapeutics, Inc. KYSA-6 Phase 2/3 Trial in gMG – Phase 2 Study Design AchR, acetylcholine receptor; Cy/Flu, cyclophosphamide and fludarabine; gMG, generalized myasthenia gravis; LRP4, low-density lipoprotein receptor-related protein 4; MG-ADL, myasthenia gravis Activities of Daily Living; MGC, Myasthenia Gravis Composite; MGFA, Myasthenia Gravis Foundation of America; MuSK, muscle-specific kinase; QMG, Quantitative Myasthenia Gravis. N = 7•Age 18 to 75 years•Diagnosis of gMG, Class IIB-IV per MGFA criteria•Autoantibodies to AChR, MuSK, or LRP4•MG-ADL ≥6•Failed ≥2 immunosuppressive/ immunomodulatory therapies OR failed ≥1 immunosuppressive therapy and required chronic plasmapheresis or IVIg to control symptoms Primary endpoints•MG-ADL at 24 weeks•Adverse eventsKey secondary endpoints•QMG and MGC scores•PK/PD Phase 2 design: Open-label, single-arm, multicenter study KYV-101Cy/Flu lymphodepletion +Single infusion of 1×108 CAR T cells 18-month follow up
Page 15
15 © 2026 Kyverna Therapeutics, Inc. MG-ADL Score QMG ScoreBaselineChange from BLWeek 2Week 24Week 52Mean MG-ADL11.0–6.9–8.3–8.2 BaselineChange from BLWeek 2Week 24Week 52Mean QMG16.9–8.6–11.7–12.8 Robust and Durable Effects Sustained Through At Least 1-Year Across MG-ADL and QMG N=7. Data cutoff: June 2026. One patient has not yet reported their MG-ADL score at 76 weeks as of the June 2026 data cutoff. Change from baseline is calculated using the baseline values of the corresponding patients at a specified timepoint.MG-ADL, myasthenia gravis activities of daily living; QMG, quantitative myasthenia gravis. 24-week primary endpointmeasurement 24-week primary endpointmeasurement
Page 16
16 © 2026 Kyverna Therapeutics, Inc. Single-dose Miv-cel Continues to Deliver Robust and Clinically Meaningful Reductions in MG Outcome Scores and Treatment Burden Substantially improved clinical outcomes 100% free of immunotherapies, including NSISTs, high-dose steroids (>10 mg), and FcRn and complement inhibitors up to 24 weeks6 of 7 patients remained free ofthese agents at last follow-up Substantially reduced gMG treatment burden MG-ADL100% had clinically meaningful response (≥2-point reduction vs baseline)100% were responders (≥3-point reduction vs baseline)57% sustained MSE at last follow-up(MG-ADL score of 0-1) QMG100% had clinically meaningful response (≥3-point reduction vs baseline)MGC100% had clinically meaningful response (≥3-point reduction vs baseline)–16.4 mean reductionat 24 weeks; –16.8 at 1year N=7. Data cutoff: June 2026.BL, baseline; FcRn, neonatal fragment crystallizable receptor; MG-ADL, myasthenia gravis activities of daily living; MGC, Myasthenia Gravis Composite; MSE, minimal symptom expression; NSIST, nonsteroidal immunosuppressive therapy; QMG, quantitative myasthenia gravis.
Page 17
17 © 2026 Kyverna Therapeutics, Inc. Consistent Safety Profile Maintained in Long-term Follow-Up With No High-Grade CRS and No ICANS or IEC-HS Treatment-related AEs, n (%)Patients (n=7)Any grade ≥3 CRS0 (0)Any grade ICANS 0 (0)Any grade IEC-HS 0 (0)SAE, any gradea 0 (0)CRS (any grade)7 (100)Grade 15 (71)Grade 22 (29)Grade 3/4 events3 (43)Neutropenia2 (29)Lymphopenia2 (29) •No high-grade CRS and no ICANS observed•No IEC-HS observed•All Grade 3/4 treatment-related AEs of neutropenia (2/7), an expected AE with lymphodepletion and CAR T-cell therapies; were not associated with infections, were manageable, and fully resolved N=7. Data cutoff: June 2026..aAfter the prior data cut (October 3, 2025), a previously reported treatment-related SAE was reclassified by the Investigator as 'not serious’, reflecting his clinical assessment of the AE per protocol-defined seriousness criteria. CRS, ICANS, IEC-HS assessed using ASTCT criteria; other AEs graded using CTCAE criteria.AE, adverse event; ASTCT, American Society for Transplantation and Cellular Therapy; CTCAE, Common Terminology Criteria for Adverse Events; CRS, cytokine release syndrome; IEC-HS, Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; SAE, serious adverse event.
Page 18
18 © 2025 Kyverna Therapeutics, Inc. | Confidential – Internal Use Only Opportunity to Achieve Drug-Free, Disease-Free Remission with Single Dose Miv-celApprovedInvestigationalFcRn Inhibitor1VYVGART®Complement Inhibitor2,3ULTOMIRIS®CD19 mAb4UPLIZNA®BCMA mRNA CAR T5Descartes-08Miv-cel CD19 CAR T(KYSA-6, n=7)Primary Endpoint4 weeks6 months6 months3 months6 monthsDepth of ResponseMean reduction from baseline to primary endpoint (non-placebo adjusted) MG-ADL Reduction~4.63.14.24.18.3QMG Reduction~6.2 2.84.83.911.7% RespondersPatients with ≥3-point MG-ADL improvement from baseline to primary endpoint (non-placebo adjusted)~73%~57%69%64%100% Achieve MSE% of patients achieving MG-ADL of 0 or 140%43%Not reported33%57% Free from chronic background immunotherapiesBCMA, b-cell maturation antigen; FcRn, neonatal fragment crystallizable receptor; mAb, monoclonal antibody; MG-ADL, myasthenia gravis activities of daily living; mRNA, messenger RNA; MSE, minimal symptom expression; QMG, quantitative myasthenia gravis score.1. Howard Jr JF, et al. Lancet Neurol. 2021;20(7):526-536. 2. Vu T, et al. NEJM Evid. 2022;1(5):EVIDoa2100066. 3. AstraZeneca. ULTOMIRIS® efficacy data from CHAMPION-MG. https://ultomirishcp.com/gmg/efficacy. Accessed 20 Aug 2025. 4. Nowak RJ, et al. N Engl J Med. 2025;392(23):2309-2320. 5. Vu T, et al. Nat Med. 2026;32:1131-1141. At any point before primary endpoint6 months to 1 yearAt any point before primary endpoint Note: These observations are derived from separate clinical settings; comparisons across trials are not based on head-to-head studies.
Page 19
Transforming the Treatment Paradigm in Neurologic Autoimmune DiseasesWarner Biddle – Chief Executive Officer ©2026 Kyverna Therapeutics, Inc.
Page 20
20 ©2026 Kyverna Therapeutics, Inc. Miv-cel’s Compelling Value Proposition Supports Strong Commercial PotentialAcross Multiple Autoimmune Diseases Today ’s Treatment ParadigmMiv-cel’s Potential - Drug-Free, Disease-Free RemissionChronic therapySingle doseInadequate disease management Immune reset Transient benefitDurable benefit beyond one yearReliance on additional immunotherapiesElimination of background immunotherapies Beyond Efficacy, Miv-cel’s Consistent and Well-Tolerated Safety Profile Increasingly Differentiates the Therapy in the Competitive Landscape
Page 21
21 Potential First-Approved Therapy for SPS Represents a Valuable Commercial Neuroimmunology Opportunity *Reflects patients who are treated with off-label Immunotherapies defined as off-label immunosuppressants (e.g., prednisone), rituximab and/or intravenous immunoglobulin. ‡Internal cumulative estimate based on assumed miv-cel pricing (premium to oncology CAR T pricing) and total diagnosed SPS patients in U.S. ATC, Academic Treatment Centers1. Crane PD, et al. Neurology. 2024;103(12):e210078. 2. HCP qualitative data and U.S. Claims Data. 3. WAC price for Yescarta®, Breyanzi®, Kymriah®, Carvykti®, Abecma®, and Aucatzyl®. Compelling SPSMarket DynamicsTargeted Launch Strategyto Maximize Value Creation •Progressive rare disease with no approved therapies •~6K U.S. diagnosed patients1; 2-2.5K immediately addressable*2•Patients concentrated at academic centers•Potential diagnosis upside •Chronic treatment, disability/job loss drive substantial economic burden on patients and society •First-in-indication rare disease launch•Expect to price miv-cel at a significant premium to existing oncology CAR T (~$500-$600K WAC3)•Targeting ~10 centers where patients are concentrated•ATC footprint expected to enable cost-effective, scalable launch execution and biologics-like margins in SPS Total U.S. Diagnosed SPS Market Represents a Multi-Billion-Dollar Rare Disease Opportunity‡
Page 22
22 ©2026 Kyverna Therapeutics, Inc. Pioneering Differentiated Therapies with Curative Potential to Free People from Life-long Autoimmune Diseases and Chronic Therapy Miv-cel BLA Submission Underway forSPSFurther strengthened by 1-year efficacy and safety data; Potential 1st approved CAR T for autoimmune and 1st approved treatment for SPS Best-in-Class ProfileUnique miv-cel construct and validated manufacturing process supporting potential for durable drug-free, disease-free remission with single, well-tolerated dose ValuableCommercial Opportunity in SPSCommercial readiness underway; immediately addressable patients; premium pricing potential Capitalized to Support Initial Miv-cel LaunchOperating runway into 2028 supporting SPS launch and gMG Phase 3 trial ©2026 Kyverna Therapeutics, Inc.PMS, progressive multiple sclerosis. Neurologic Autoimmune StrategyFocused franchise strategy prioritizing SPS, MG, and PMS Innovation to Expand AccessPotential for new indications and delivery mechanisms, including alternative preconditioning and manufacturing enhancements
Page 23
Q&AWarner BiddleChief Executive OfficerNaji Gehchan, M.D., MSc, MBAChief Medical& Development Officer Greg MartiniChief Financial Officer ©2026 Kyverna Therapeutics, Inc.
Page 24
Appendix
Page 25
25 ©2026 Kyverna Therapeutics, Inc. Single Dose Miv-cel Demonstrates Potential To Deliver Drug-Free, Disease-Free Remission to Patients with SPS, a Disease with No Approved Therapies Consistent, well-tolerated, and manageable safety profile, continues to support potential for outpatient administration Immunomodulatory or immunosuppressant therapies include IVIg/SCIg, PLEX, rituximab and/or prednisone (≥20 mg/day) for SPS symptoms. Continued reversal of disability observed out to 1 year Sustained improvements through 1 year across all primary and secondary endpoints resulting from deep B-cell depletion and potential for immune reset Nearly all patients treated remain free of chronic immunomodulatory or immunosuppressant therapies for SPS, substantially reducing treatment burden 1-Year Durability and Safety Data Further Strengthen BLA Submission, Anticipated to be Completed in Q4 2026
Page 26
26 ©2026 Kyverna Therapeutics, Inc. gMG Data Further Reinforces Potential for Miv-Cel to Provide Broad Immune Reset with a Single Dose, Increasing Confidence in Phase 3 Trial Consistent, well-tolerated, and manageable safety profile continues to support potential for outpatient administration Chronic background immunotherapies include NSISTs (nonsteroidal immunosuppressive therapy), high-dose steroids (>10 mg), and FcRn (neonatal fragment crystallizable receptor) and complement inhibitors.MG-ADL, myasthenia gravis activities of daily living; MSE, minimal symptom expression; QMG, quantitative myasthenia gravis. Majority of patients maintained MSE as of last follow-up Robust and durable effects sustained through at least 1 year further differentiate miv-cel from existing chronic therapies Nearly all patients remain free of chronic immunotherapies, substantially reducing treatment burden Positioned to Potentially be the First CD19 Autologous CAR T to be Approved in gMG, Transforming the Treatment Paradigm
Page 27
27 Primary Endpoint Outcome Assesses Impact of SPS on Walking AbilityTimed 25-Foot Walk (T25FW) •Validated tool to assess walking ability1•Used to evaluate stiffness and loss of mobility in SPS2•Healthy adults can perform the T25FW in ~4-5 seconds3 1. Hobart J, et al. Neurology. 2013; 80: 1509-1517. 2. Newsome SD and Johnson T J. Neuroimmunol. 2022;369:577915. 3. Motl RW, et al. Mult Scler J. 2017; 23(5): 704-710. 25 FEETSTART/STOP START/STOP TURN AROUNDFIRST WALK SECOND WALK T25FW = Average of 2 Walks 20% improvement considered clinically meaningful1
Page 28
28 Secondary Endpoint Outcomes Assess Extent of Disability and SPS-Specific SymptomsModified RankinScale (mRS)0 612345 No symptomsNonsignificantDisabilitySlight Disability DeathSevereDisabilityModerately SevereDisabilityModerateDisability Degree of disability1 T25FW, timed 25-foot walk; WC, wheelchair.1. vanSwietinJC, et al.Stroke. 1988; 19(5): 604-607. 2. Hauser SL, et al. New Engl J Med. 1983; 308(4): 173-180. 3. Dalakas MC, et al. N Engl J Med. 2001; 345(26): 1870-1876. 4. Dalakas MC, et al. Ann Neurol. 2017; 82(2): 271-277. Hauser Ambulation Index (HAI)Time and degree of assistance to complete T25FW2 Distribution-of-StiffnessIndex (DSI)Muscle stiffness across body regions3,4 Heightened Sensitivity Scale (HSS)Number of triggers of muscle spasms3,4 No symptomsFatigueAbnormal gaitT25FW ≤10sNo SupportT25FW ≤20sUnilateral supportT25FW ≤20sUnilateral supportT25FW >20s*Bilateral supportT25FW >20s†Cannot walk 25ftFrequent WC useRestricted to WCCan self transferRestricted to WCNo self transfer 0123456789 1 point for each stiff body region (0-6) 1 point for each trigger/stimulus (1-7)
Page 29
29 © 2025 Kyverna Therapeutics, Inc. | Confidential – Internal Use Only ~60-patient, global, open-label, randomized controlled Phase 2/3 trial with crossover design Miv-celLow-dose Cy/Flu preconditioning +Single infusion of 1×108 CAR T cells Standard of CareTraditional agents or complement pathway inhibitors N = ~60Randomized1:1 Baseline Measurement Screening, washout, apheresis, and resume standard of care 24 weeks18 Months Co-Primary Endpoints(MG-ADL & QMG) Miv-cel Crossover Follow Up Follow Up Standard of care may consist of traditional agents (e.g., prednisone, azathioprine, mycophenolate, methotrexate, chronic IVIg/PLEX) or complement pathway inhibitors (e.g., eculizumab, ravulizumab). Anti-CD20 or -CD19 monoclonal antibodies or FcRn inhibitors not allowed as defined in inclusion criteria.Cy/Flu, cyclophosphamide and fludarabine; FcRn, neonatal fragment crystallizable receptor; IVIg, intravenous immunoglobulin; MG-ADL, myasthenia gravis activities of daily living; PLEX, plasma exchange; QMG, quantitative myasthenia gravis score. © 2026 Kyverna Therapeutics, Inc. KYSA-6 Phase 2/3 Trial in gMG – Phase 3 Study Design